Cargando…

From Genes, Proteins, and Clinical Manifestation: Why Do We Need to Better Understand Age-Related Macular Degeneration?

Detalles Bibliográficos
Autores principales:	Schmitz-Valckenberg, Steffen, Zouache, Moussa A., Hageman, Gregory S., Fleckenstein, Monika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560631/ https://www.ncbi.nlm.nih.gov/pubmed/36249706 http://dx.doi.org/10.1016/j.xops.2022.100174

Ejemplares similares

Progression of Age-Related Macular Degeneration Among Individuals Homozygous for Risk Alleles on Chromosome 1 (CFH-CFHR5) or Chromosome 10 (ARMS2/HTRA1) or Both
por: Schmitz-Valckenberg, Steffen, et al.
Publicado: (2022)

Macular retinal thickness differs markedly in age-related macular degeneration driven by risk polymorphisms on chromosomes 1 and 10
por: Zouache, Moussa A., et al.
Publicado: (2020)

Author Correction: Macular retinal thickness differs markedly in age-related macular degeneration driven by risk polymorphisms on chromosomes 1 and 10
por: Zouache, Moussa A., et al.
Publicado: (2021)

Prognostic value of intermediate age-related macular degeneration phenotypes for geographic atrophy progression
por: Thiele, Sarah, et al.
Publicado: (2021)

Evaluation of Two Systems for Fundus-Controlled Scotopic and Mesopic Perimetry in Eye with Age-Related Macular Degeneration
por: Steinberg, Julia S., et al.
Publicado: (2017)

AI-based structure-function correlation in age-related macular degeneration
por: von der Emde, Leon, et al.
Publicado: (2021)

Longitudinal Analysis of Structural and Functional Changes in Presence of Reticular Pseudodrusen Associated With Age-Related Macular Degeneration
por: Sassmannshausen, Marlene, et al.
Publicado: (2020)

Determinants of Quality of Life in Geographic Atrophy Secondary to Age-Related Macular Degeneration
por: Künzel, Sandrine H., et al.
Publicado: (2020)

Mesopic and Dark-Adapted Two-Color Fundus-Controlled Perimetry in Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
por: von der Emde, Leon, et al.
Publicado: (2018)

Artificial intelligence for morphology-based function prediction in neovascular age-related macular degeneration
por: von der Emde, Leon, et al.
Publicado: (2019)

Re: Trivizki et al. Local Geographic Atrophy Growth Rates Not Influenced by Close Proximity to Non-Exudative Type 1 Macular Neovascularization
por: Pfau, Maximilian, et al.
Publicado: (2022)

Clinical and Genetic Factors Associated with Progression of Geographic Atrophy Lesions in Age-Related Macular Degeneration
por: Grassmann, Felix, et al.
Publicado: (2015)

Protective chromosome 1q32 haplotypes mitigate risk for age-related macular degeneration associated with the CFH-CFHR5 and ARMS2/HTRA1 loci
por: Pappas, Chris M., et al.
Publicado: (2021)

Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration
por: Pfau, Maximilian, et al.
Publicado: (2021)

Improved sensitivity of microperimetric outcomes for clinical studies in age-related macular degeneration
por: Barkana, Yaniv, et al.
Publicado: (2021)

Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy
por: Pfau, Maximilian, et al.
Publicado: (2022)

Why do we need better omics in the breast cancer care?
por: Gertych, Arkadiusz, et al.
Publicado: (2021)

Why we need to better understand the cortical neurophysiology of impaired postural responses with age, disease, or injury
por: Jacobs, Jesse V.
Publicado: (2014)

Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson’s and Alzheimer’s Disorders?
por: Youdim, Moussa B. H.
Publicado: (2010)

Automated Retinal Image Analysis for Evaluation of Focal Hyperpigmentary Changes in Intermediate Age-Related Macular Degeneration
por: Schmitz-Valckenberg, Steffen, et al.
Publicado: (2016)

Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany
por: Wachtlin, Joachim, et al.
Publicado: (2020)

Why we need a Public Understanding of Social Science
por: Lewis, Jamie, et al.
Publicado: (2023)

Algorithms for the Automated Analysis of Age-Related Macular Degeneration Biomarkers on Optical Coherence Tomography: A Systematic Review
por: Wintergerst, Maximilian W.M., et al.
Publicado: (2017)

An update on the genetics of age-related macular degeneration
por: Scholl, Hendrik P.N., et al.
Publicado: (2007)

Why do we need Cases Journal?
por: Smith, Richard
Publicado: (2008)

Why do we need a…Journal?
por: Gopikrishna, Velayutham
Publicado: (2009)

Why do we need male contraceptives?
por: Cheng, C Yan, et al.
Publicado: (2013)

Lifestyle Medicine: Why Do We Need It?
por: Pijl, Hanno
Publicado: (2018)

Why Do We Need Royal Colleges?
por: Adams, Aileen K
Publicado: (1999)

Relative ellipsoid zone reflectivity and its association with disease severity in age-related macular degeneration: a MACUSTAR study report
por: Saßmannshausen, Marlene, et al.
Publicado: (2022)

Intersession Repeatability of Structural Biomarkers in Early and Intermediate Age-Related Macular Degeneration: A MACUSTAR Study Report
por: Saßmannshausen, Marlene, et al.
Publicado: (2022)

Gallbladder Cancer: We Need to Do Better!
por: Shukla, Parul J., et al.
Publicado: (2009)

Do We Need Biomarkers for Disc Degeneration?
por: Gruber, Helen E., et al.
Publicado: (2007)

Medical marijuana programs — Why might they matter for public health and why should we better understand their impacts?
por: Fischer, Benedikt, et al.
Publicado: (2015)

Why we need a deeper understanding of the pathophysiology of long COVID
por: Iwasaki, Akiko, et al.
Publicado: (2023)

Why do we Need Quality Articles, What are we Going to do With?
por: Mueen Ahmed, KK
Publicado: (2011)

Comparability of automated drusen volume measurements in age-related macular degeneration: a MACUSTAR study report
por: Garzone, Davide, et al.
Publicado: (2022)

Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson's and Alzheimer's Diseases as Disease Modifying Agents
por: Youdim, Moussa B. H.
Publicado: (2010)

Why do we need improved mobility technology?
por: Boninger, Michael L, et al.
Publicado: (2012)

What is vitamin A and why do we need it?
por: Gilbert, Clare
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_61u0olhhlijugqk58klcu4r4co